key: cord-0774234-cg74ap6g
authors: Kim, Dong-Min; Kim, Yuri; Seo, Jun-Won; Lee, Jooyeon; Park, Uni; Ha, Na-Young; Koh, Jaemoon; Park, Hyoree; Lee, Jae-Won; Ro, Hyo-Jin; Yun, Na Ra; Kim, Da Young; Yoon, Sung Ho; Na, Yong Sub; Moon, Do Sik; Lim, Sung-Chul; Kim, Choon-Mee; Jeon, Kyeongseok; Kang, Jun-Gu; Jang, Na-Yoon; Jeong, Hyeongseok; Kim, Jungok; Cheon, Shinhyea; Sohn, Kyung Mok; Moon, Jae Youg; Kym, Sungmin; Han, Seung Ro; Lee, Myung-Shin; Kim, Hyun-Je; Park, Woong-Yang; Choi, Ji-Yeob; Shin, Hyun-Woo; Kim, Hye-Young; Cho, Chung-Hyun; Jeon, Yoon Kyung; Kim, Yeon-Sook; Cho, Nam-Hyuk
title: Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19
date: 2021-09-20
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109798
sha: d2e7c55e838db8c13a1886f19097e0f10aaab512
doc_id: 774234
cord_uid: cg74ap6g

Despite the worldwide effect of the Coronavirus disease 2019 (COVID-19) pandemic, the underlying mechanisms of fatal viral pneumonia remain elusive. Here, we show that critical COVID-19 is associated with enhanced eosinophil-mediated inflammation when compared to non-critical cases. In addition, we confirm increased Th2-biased adaptive immune responses, accompanying overt complement activation, in the critical group. Moreover, enhanced antibody responses and complement activation is associated with disease pathogenesis as evidenced by formation of immune complexes and membrane attack complexes in airways and vasculature of lung biopsies from six fatal cases, as well as by enhanced hallmark gene set signatures of FcγR signaling and complement activation in myeloid cells of respiratory specimens from critical COVID-19 patients. These results suggest that SARS-CoV-2 infection may drive specific innate immune responses, including eosinophil-mediated inflammation, and subsequent pulmonary pathogenesis via enhanced Th2-biased immune responses, which might be crucial drivers of critical disease in COVID-19 patients.

To investigate the potential causative factors driving severe pulmonary inflammation during the 134 acute phase of COVID-19, we tried to directly analyze the inflammatory cells and mediators in 135 respiratory specimens. 45 BALFs and sputa samples collected from patient groups 1 and 2 at Table S2 ). Despite a wide variation among the specimens, BALFs and sputa from COVID-19 139 patients mainly contained PMNs (mostly neutrophils, mean ± S.D.: 46.8 ± 34.3% in total 140 leukocytes), monocytes/macrophages (37.5 ± 32.7%), and a few lymphocytes (11.6 ± 12.2%). 141 We also observed eosinophils (4.3 ± 7.3%) in 48.9% (22/45) of the respiratory specimens ( Fig.   142 2a, 2b, and Supplementary Table S2 ). When we compared the level of each inflammatory cell 143 type between non-critical and critical patients, the relative proportion of all the cell types were 144 not significantly different between the groups, although eosinophils were slightly higher in the 145 non-critical group (6.0 ± 9.4%) than critical patients (2.8 ± 4.6%, p = 0.18) (Supplementary 146   Table S2 ). 147 To assess the kinetic changes of immune cell types in respiratory specimens of COVID-19 148 patients, the relative proportion of each cell type was measured over time after symptom onset by after symptom onset, whereas their infiltration was rather delayed and peaked during D10-20 in potentially with a M2 phenotype, during the early phase of critical COVID-19 pneumonia (Zeng 180 et al., 2020). In addition, cytotoxic activity of CTLs and NK cells was not significantly different 181 between critical and non-critical groups, when assessed by measuring granzyme A in respiratory 182 specimens (Fig. 2h) . These results show that there is an acute spike in macrophage activation 183 during the early phase of critical COVID-19 pneumonia and highlight the significant 184 contribution of enhanced and sustained eosinophil-mediated inflammation (Merad and Martin, 185 2020). 186 When we compared the levels of inflammatory mediators between younger (≤59) and older age 187 (≥60) group, the only significant difference was in EDN, which was significantly higher in the 188 younger group than elderly patients ( Supplementary Fig. S1c -S1i). However, the difference was 189 not significant when they were further accounting for disease severity ( Supplementary Fig. S1h ). 190 Nevertheless, it is interesting to note that the levels of ECP was significantly higher in elderly 191 patients than younger patients with critical COVID-19 ( Supplementary Fig. S1g ). 192 We also assessed the potential correlation of inflammatory mediators with viral loads in the same 216 To further define pulmonary inflammation associated with COVID-19 patients, we examined 217 multiple cytokines, chemokines, and inflammatory mediators in 31 respiratory samples, 218 including sputa and BALFs, collected from 11 patients (6 non-critical cases and 5 critical cases 219 in group 1) at various time points after symptom onset ( Fig. 3a and Supplementary Fig. S3 ). Group II contains IL-1, IL-2, IL-7, IL-8, IL-15, TNF-, CCL4 (MIP-1 chemokines between critical and non-critical groups, only three inflammatory markers, IL-6 236 (mean ± S.D.: 2.8 ± 8.1 vs. 9.1 ± 14.1 ng/ml for non-critical and critical group, respectively), 237 TGF-(0.9 ± 1.9 vs. 3.2 ± 4.0 ng/ml for non-critical and critical group, respectively), and ECP 238 (as noted above), were significantly higher in critical patients than the non-critical group ( Mazzoni et al., 2020). Our data confirms a significant association of this inflammatory cytokine 242 with disease severity even in the respiratory environment of COVID-19 patients. In addition, IL-243 6 was broadly and significantly associated with pro-inflammatory cytokines, as well as type 2 244 cytokines. ECP was significantly correlated with pro-inflammatory cytokines, including IL-1, 245 IL-6 and TNF-, in addition to type 2 cytokines, such as IL-4 and IL-13 (Fig. 3a) , suggesting a potential association of eosinophil-mediated inflammation with cytokine release syndrome and 247 type 2 immune responses. TGF-was barely correlated with any other soluble markers, although 248 it was grouped with type 2 cytokines. Given the functional role of TGF-in mucosal immunity for M1 phenotype in the non-critical group than those of critical cases, while conversely the gene 265 set scores for M2 phenotype were significantly increased in critical cases than the non-critical 266 group (Fig. 3f ). In addition, the hallmark gene set scores for Th2 responses were significantly 267 elevated in the critical group than non-critical cases (Fig. 3g) . Those for Th1 responses were also 268 J o u r n a l P r e -p r o o f generally higher in critical patients than the non-critical group, whereas the difference for Th17 269 responses was not statistically significant between non-critical and critical patients. These results were generally higher in plasma from critical patients (7.9 ± 1.3 g/ml and 50.5 ± 20.3 ng/ml for 303 C3a and C5a, respectively) than from the non-critical group (1.2 ± 2.0 g/ml and 38.9 ± 30.1 304 ng/ml for C3a and C5a, respectively) (Fig. 4e) . The difference in C5a levels between critical and 305 non-critical groups was statistically significant, as previously reported (Carvelli et al., 2020) . In 306 addition, we observed a significant positive correlation of C5a levels with plasma IgG1 and IgG3 307 levels (Fig. 4f) . These results confirm that viral antigen-specific antibody responses are 308 significantly higher in plasma from critical patients than the non-critical group, as previously Supplementary Fig. S6a) . Interestingly, type I IFN 396 response in the pulmonary leukocytes in the critical group was initially suppressed during the 397 first 10 D after symptom onset, but there was a more robust rebound thereafter when compared 398 non-critical cases (Supplementary Fig. S6a) . We observed a similar trend in gene set activity of 399 Th2 responses ( Supplementary Fig. S6d) , whereas more enhanced M2 activity was consistently 400 detected throughout the symptomatic period in the critical group ( Supplementary Fig. S6c ).

Mechanistic and correlation studies using more data sets of pulmonary inflammation markers followed by systemic IgG responses (peak at D20-30) in critical cases. In contrast, all these 417 isotypes peaked at D20-30 in plasma from non-critical group patients (Fig. 4d) . Moreover, patients. When we analyzed scRNA seq data sets from mononuclear phagocytes and neutrophils, there were significantly higher levels of hallmark gene set scores for both FcγR signaling and 451 complement activation in the critical group than non-critical cases (Fig. 7) . These results clearly 

Dysregulation of type I interferon responses in 758 COVID-19

TGF-beta receptor signaling is 760 critical for mucosal IgA responses

The role of IgG Fc receptors in antibody-762 dependent enhancement

Association of COVID-19 inflammation with 765 activation of the C5a-C5aR1 axis

COVID-19 severity correlates with airway 768 epithelium-immune cell interactions identified by single-cell analysis

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory 772

Syndrome Coronavirus 2 (SARS-CoV-2c)

Complement activation in patients with COVID-775 19: A novel therapeutic target

Acute Eosinophilic Pneumonia

IL-6: 779 Relevance for immunopathology of SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Patients with Idiopathic Pulmonary

Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses

Loss of Bcl-6-Expressing T Follicular

Helper Cells and Germinal Centers in COVID-19

The type I interferon response in COVID-19: implications for 791 treatment

Eosinophilic Panniculitis Associated With COVID-19

SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 796 (COVID-19)

Single-cell landscape of bronchoalveolar immune cells in patients with

Eosinophil responses during

COVID-19 infections and coronavirus vaccination

Antibody responses to SARS-CoV-2 in patients with COVID-19

Longitudinal analyses reveal immunological misfiring in 807 severe COVID-19

Complement associated microvascular injury and thrombosis in the 810 pathogenesis of severe COVID-19 infection: A report of five cases

Impaired immune cell cytotoxicity in severe COVID-813 19 is IL-6 dependent

Pathological inflammation in patients with COVID-19: a 815 key role for monocytes and macrophages